^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    MUC16 inhibitor

    Related drugs:
    1d
    Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Oct 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • OvaRex (oregovomab)
    4d
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)
    6d
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    7d
    Compassionate Use of Ubamatamab (clinicaltrials.gov)
    P=N/A, N=0, Available, Regeneron Pharmaceuticals
    New trial
    |
    ubamatamab (REGN4018)
    11d
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    5ms
    A Phase Ib Study of Indirect Immunization with Oregovomab and Toll-like-Receptor-3 Stimulation with Hiltonol® in Patients with Recurrent Platinum-Resistant Ovarian Cancer. (PubMed, Curr Oncol)
    The safety and compatibility of combining oregovomab with Hiltonol® have been demonstrated in this study. The potential to enhance activity of chemotherapy using oregovomab indirect immunization and Hiltonol® stimulation is proposed.
    P1 data • Journal • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated) • TLR3 (Toll Like Receptor 3)
    |
    Hiltonol (poly-ICLC) • OvaRex (oregovomab)
    7ms
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, Regeneron Pharmaceuticals
    New P2 trial
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    8ms
    Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes. (PubMed, JCO Precis Oncol)
    MUC16 is frequently detected in ES and MRTs. Ubamatamab is an encouraging anti-MUC16 therapy, demonstrating clinical efficacy. Ongoing trials (ClinicalTrials.gov identifier: NCT06444880) are evaluating ubamatamab in other rare MUC16-positive tumors.
    Retrospective data • Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018)
    9ms
    R4018-ONC-1721: Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (clinicaltrials.gov)
    P1/2, N=890, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Libtayo (cemiplimab-rwlc) • Actemra IV (tocilizumab) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    9ms
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Sep 2027 | Trial primary completion date: Sep 2024 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    9ms
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)